Phase II study of bevacizumab plus irinotecan and carboplatin for recurrent WHO grade 3 malignant gliomas with no prior bevacizumab failure.

Conference Paper

Full Text

Duke Authors

Cited Authors

  • Desjardins, A; Vredenburgh, JJ; Peters, KB; Threatt, S; Herndon, JE; Sampson, JH; Friedman, AH; Friedman, HS; Reardon, DA

Published Date

  • May 20, 2012

Published In

Volume / Issue

  • 30 / 15

Electronic International Standard Serial Number (EISSN)

  • 1527-7755

International Standard Serial Number (ISSN)

  • 0732-183X